PCOS Healthcare Trends · Trends and research

GLP-1 medicines and PCOS/PMOS: what patients are asking, what a new review found

Few topics now come up in PCOS/PMOS appointments as often as GLP-1 medicines. Patients are asking about them in clinics and in patient communities, clinics report the same rising volume of questions, and researchers are publishing reviews to map what has actually been studied. This piece does two things only: it reports that trend, and it walks through the newest map of the research — a scoping review published in September 2026 — in plain language, including the limits its own authors put up front. It makes no claim about whether any medicine is right for any person.

First, the trend itself — reported as a trend

When we say more patients are asking about GLP-1 medicines, we mean exactly that: the volume of questions has risen. A question trend tells you what people want to understand. It does not tell you whether a medicine works, for whom, or at what risk — those are research and clinical questions, and they are the rest of this page. Our glossary covers the surrounding terms — insulin resistance, androgens, and metabolic syndrome — in plain language, and our explainer on insulin resistance in PCOS/PMOS explains why metabolic topics sit at the centre of so many of these conversations.

What “GLP-1 medicine” means, in one paragraph

GLP-1 is short for glucagon-like peptide-1, a hormone signal the gut releases after eating that is involved in insulin release and appetite signalling. Medicines in this class — called GLP-1 receptor agonists — are designed to act on that same signal. They were developed for diabetes and weight-related care in the general population. The 2023 International Evidence-based Guideline for PCOS/PMOS does not frame them as a treatment for the condition itself; as summarised below, it frames them as one option clinicians could consider for managing higher weight in adults with this condition, under general-population guidance.

The new map: a scoping review of 28 studies

In September 2026, researchers at Nova Southeastern University published a scoping review in Cureus on the reproductive and gynaecologic side of this literature. A scoping review is a map, not a verdict: its job is to gather what exists and describe its shape, not to pool results into one bottom-line number. The authors searched four databases, screened 1,416 records, and included 28 studies of GLP-1 medicines in women with PCOS/PMOS that reported reproductive or gynaecologic outcomes.

What the map shows about the shape of the research:

Those are the review’s descriptions of its included studies, reported here as the authors presented them. A scoping review, by its own design, does not grade how strong each study was — and this page does not upgrade its map into a promise.

What the authors themselves flagged as unknown

What the guideline actually says — and does not say

The 2023 International Evidence-based Guideline — the reference clinicians are pointed to for this condition, maintained by the program at Monash University — says, in its own wording as widely summarised, that anti-obesity medicines including liraglutide and semaglutide “could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines.” Three parts of that sentence matter:

The guideline framing also leaves out an important group by design: it is about adults with higher weight. It says nothing that turns these medicines into a topic for every patient — including lean patients, for whom weight is not part of their picture and whose questions are usually about cycles, skin and hair, fertility timing, and metabolic screening instead.

What this does not mean

Which clinician handles which part of this conversation

What this means when you are finding care

A provider page that discusses metabolic health, weight, and screening in the measured terms the guideline uses — an option to consider, with open questions named — is describing this topic the way the current literature does. You can search the directory for PCOS/PMOS-focused providers, browse by state — for example, the Florida listings page — and use the plain-language glossary before a visit.

Questions worth asking your provider

Sources

Looking for care? Find a PCOS/PMOS-focused provider or browse by state.

This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.